These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19689250)

  • 1. Effects of acarbose on proinsulin and insulin secretion and their potential significance for the intermediary metabolism and cardiovascular system.
    Rosak C; Mertes G
    Curr Diabetes Rev; 2009 Aug; 5(3):157-64. PubMed ID: 19689250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus.
    Inoue I; Takahashi K; Noji S; Awata T; Negishi K; Katayama S
    Diabetes Res Clin Pract; 1997 Jun; 36(3):143-51. PubMed ID: 9237780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
    Zeymer U
    Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of acarbose treatment on markers of insulin sensitivity and systemic inflammation.
    Rudovich NN; Weickert MO; Pivovarova O; Bernigau W; Pfeiffer AF
    Diabetes Technol Ther; 2011 Jun; 13(6):615-23. PubMed ID: 21488802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes.
    Hanefeld M; Haffner SM; Menschikowski M; Koehler C; Temelkova-Kurktschiev T; Wildbrett J; Fischer S
    Diabetes Res Clin Pract; 2002 Mar; 55(3):221-7. PubMed ID: 11850098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral antidiabetic agents as cardiovascular drugs.
    Macfarlane DP; Paterson KR; Fisher M
    Diabetes Obes Metab; 2007 Jan; 9(1):23-30. PubMed ID: 17199715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.
    Rosak C; Hofmann U; Paulwitz O
    Diabetes Nutr Metab; 2004 Jun; 17(3):137-42. PubMed ID: 15334790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Acarbose--an effective drug for the prevention of type 2 diabetes and cardiovascular diseases?].
    Laakso M
    Duodecim; 2003; 119(20):1921-3. PubMed ID: 14639996
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
    Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
    Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
    JAMA; 2003 Jul; 290(4):486-94. PubMed ID: 12876091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits.
    Hanefeld M; Schaper F
    Expert Rev Cardiovasc Ther; 2008 Feb; 6(2):153-63. PubMed ID: 18248270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study.
    Shimabukuro M; Higa N; Chinen I; Yamakawa K; Takasu N
    J Clin Endocrinol Metab; 2006 Mar; 91(3):837-42. PubMed ID: 16368744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes.
    Wagner H; Degerblad M; Thorell A; Nygren J; Ståhle A; Kuhl J; Brismar TB; Ohrvik J; Efendic S; Båvenholm PN
    Diabetes Care; 2006 Jul; 29(7):1471-7. PubMed ID: 16801564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease.
    Haffner SM
    Endocr Rev; 1998 Oct; 19(5):583-92. PubMed ID: 9793758
    [No Abstract]   [Full Text] [Related]  

  • 16. [Postprandial blood glucose as the driving force in pathogenesis of type 2 diabetes].
    Liebl A
    Med Klin (Munich); 2003 Oct; 98 Suppl 1():7-11. PubMed ID: 14694835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review.
    Joshi SR; Standl E; Tong N; Shah P; Kalra S; Rathod R
    Expert Opin Pharmacother; 2015; 16(13):1959-81. PubMed ID: 26255950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes.
    Breuer HW
    Int J Clin Pharmacol Ther; 2003 Oct; 41(10):421-40. PubMed ID: 14703948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders.
    Yamagishi S; Matsui T; Ueda S; Fukami K; Okuda S
    Curr Drug Metab; 2009 Feb; 10(2):159-63. PubMed ID: 19275550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes.
    Hanefeld M
    Cardiovasc Diabetol; 2007 Aug; 6():20. PubMed ID: 17697384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.